ClinicalTrials.gg
RecruitingNCT07259512Updated Dec 10, 2025

Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

A Phase 4 interventional study of Ramipril in Chronic Kidney Disease and Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by Evi Liliek Wulandari. Recruiting at 1 site in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Evi Liliek Wulandari · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Jun 2025, registered Nov 2025).
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Renal Insufficiency, Chronic with a site in Indonesia — 6 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Indonesia.

Planned enrollment
5th of 16
80 · median 45
Started
2025
with 2 others
Phase 4
2 of 23
1 open now
Registered
15th of 23
by date
Lead sponsor
1 of 23
Evi Liliek Wulandari

Among the 23 studies in Renal Insufficiency, Chronic with a site in Indonesia, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 4, and was the 15th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 23 studies in Renal Insufficiency, Chronic with a site in Indonesia are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Renal Insufficiency, Chronic with a site in Indonesia, or all of them as a file.
02

Study summary

This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.

Read the detailed description

Chronic kidney disease (CKD) frequently coexists with heart failure with reduced ejection fraction (HFrEF), characterized by neurohormonal activation, inflammation, oxidative stress, and progressive renal deterioration. Activation of the renin-angiotensin-aldosterone system (RAAS) contributes significantly to both renal and cardiac dysfunction. Ramipril, an ACE inhibitor, is widely recommended for CKD with albuminuria and HFrEF. However, discrepancies exist in guidelines regarding once-daily versus twice-daily administration. These differences may influence RAAS suppression effectiveness and patient adherence.

This randomized, double-blind, parallel assignment clinical trial investigates the impact of once-daily (10 mg every 24 hours) versus twice-daily (5 mg every 12 hours) ramipril dosing on renal biomarkers in CKD patients with HFrEF. Outcomes include plasma renin activity (PRA), malondialdehyde (MDA), interleukin-6 (IL-6), albuminuria, and cystatin C measured over a 30-day treatment period. The study aims to provide scientific evidence to support optimal ramipril dosing strategies that improve renal outcomes among patients with CKD and reduced ejection fraction heart failure.

03

Conditions studied

  • Chronic Kidney Disease
  • Heart Failure With Reduced Ejection Fraction (HFrEF)

Keywords

  • Chronic Kidney Disease
  • HFrEF
  • Ramipril
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or Male with age >18 years old
  • Patients with a diagnosis of CKD stage 3-5 non-dialysis with low heart failure (ejection fraction \< 40%)

Exclusion criteria

Exclusion Criteria:

  • Receiving hemodialysis therapy
  • History of intolerance to ACE inhibitors
  • hyperkalemia
  • Pregnancy
  • History of angioedema to ACE inhibitors
  • Receiving sacubitril-valsartan therapy
  • Receiving ARB therapy
  • Hypotension with blood pressure \<90/60, or patients in shock.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Once-Daily Ramipril

    Participants receive ramipril 10 mg once daily for 30 days

    Drug: Ramipril

  • Experimental
    Twice-Daily Ramipril

    Participants receive ramipril 5 mg twice daily for 30 days

    Drug: Ramipril

Interventions

  • Ramipril administered either as 10 mg once daily or 5 mg twice daily for 30 days

    Also known as: ACE inhibitor

06

What researchers measure

Primary outcomes

  1. Change in Plasma Renin Activity (PRA)

    Change in plasma renin activity from baseline to day 30.

    Time frame: 30 days

  2. Change in Malondialdehyde (MDA)

    Change in plasma MDA levels as a biomarker of oxidative stress

    Time frame: 30 days

  3. Change in Interleukin-6 (IL-6)

    Change in serum IL-6 levels as a marker of systemic inflammation

    Time frame: 30 days

  4. Change in Albuminuria

    Change in albumin-creatinine ratio (ACR) from baseline to day 30

    Time frame: 30 days

  5. Change in Cystatin C

    Change in serum cystatin C levels as a marker of glomerular filtration

    Time frame: 30 days

Secondary outcomes

  1. Change in Serum Creatinine

    Change in serum creatinine concentration from baseline to day 30, measured by standard hospital laboratory methods

    Time frame: 30 days

  2. Change in Estimated Glomerular Filtration Rate (eGFR)

    Change in estimated glomerular filtration rate (eGFR) from baseline to day 30, calculated using the CKD-EPI equation

    Time frame: 30 days

  3. Change in Blood Pressure (Systolic and Diastolic)

    Change in clinic-measured systolic and diastolic blood pressure from baseline to day 30

    Time frame: 30 days

  4. Incidence of Treatment-Related Adverse Events

    Number and type of adverse events considered related to ramipril during 30 day treatment period (e.g. hyperkalemia), graded by severity

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • UNS Hospital
    Kartasura, Central Java, Indonesia
    Recruiting
08

References and documents

Publications

  • Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019. No abstract available. PubMed 32998798 ↗
  • Ariton DM, Jimenez-Balado J, Maisterra O, Pujadas F, Soler MJ, Delgado P. Diabetes, Albuminuria and the Kidney-Brain Axis. J Clin Med. 2021 May 27;10(11):2364. doi: 10.3390/jcm10112364. PubMed 34072230 ↗
  • Kreiner FF, Kraaijenhof JM, von Herrath M, Hovingh GKK, von Scholten BJ. Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. Expert Rev Clin Immunol. 2022 Apr;18(4):377-389. doi: 10.1080/1744666X.2022.2045952. Epub 2022 Mar 1. PubMed 35212585 ↗
  • Jakopin E, Knehtl M, Hojs NV, Bevc S, Piko N, Hojs R, Ekart R. Treatment of acute kidney injury with continuous renal replacement therapy and cytokine adsorber (CytoSorb(R)) in critically ill patients with COVID-19. Ther Apher Dial. 2024 Dec;28(6):941-950. doi: 10.1111/1744-9987.14182. Epub 2024 Jul 3. PubMed 38958006 ↗
  • Nijst P, Verbrugge FH, Martens P, Bertrand PB, Dupont M, Francis GS, Tang WW, Mullens W. Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. J Renin Angiotensin Aldosterone Syst. 2017 Jul-Sep;18(3):1470320317729919. doi: 10.1177/1470320317729919. PubMed 28875746 ↗
  • Arifiyanto, A. Y., Dwi Laksono, A., Chalidyanto, D., Taniasari, N., & Kusumaningtyas, W. (2021). Factors Related to the Prevalenceof Chronic Kidney Disease in Indonesia:An Ecological Study. Indian Journal of Forensic Medicine & Toxicology, 15(3), 1867-1873.
  • Tedeschi A, Agostoni P, Pezzuto B, Corra' U, Scrutinio D, La Gioia R, Raimondo R, Passantino A, Piepoli MF. Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):35-45. doi: 10.1177/2047487320957793. PubMed 33238740 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 6 months after the start.

Of 101 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 65. This study's planned 6 months is below that.

Counting every sponsor, half of 117 studies reached it within 43 months; a quarter within 22 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 2, 2025
StartActual
Jun 30, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jan 31, 2026
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259512
Lead sponsor
Evi Liliek Wulandari
Responsible party
Evi Liliek Wulandari (Principal Investigator, Consultant Internist (Internal Medicine Specialist), Universitas Sebelas Maret) — Sponsor-investigator
First posted
Dec 2, 2025
Start date
Jun 30, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Dec 10, 2025

Study contacts

Evi L Wulandari, MD., Internist
Contact
evililiek@staff.uns.ac.id
(+62)821-3587-2749

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramipril

Start the discussion